Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
Wei Teng(Harbin Medical University), Jaw‐Ching Wu(National Yang Ming Chiao Tung University), Chien‐Wei Su(National Yang Ming Chiao Tung University), Hwai‐I Yang(Chang Gung University), Tsung‐Hui Hu(National Sun Yat-sen University), Cheng‐Yuan Peng(China Medical University), Ming‐Lung Yu(National Sun Yat-sen University), Hung‐Chih Yang(Johns Hopkins University), Ting‐Tsung Chang(National Cheng Kung University Hospital), Tung‐Hung Su(National Taiwan University)
Cited by 27
Related Papers
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load
|Gastroenterology|2006|1.5k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
|Gastroenterology|2006|882